Piazu PIAra Merukari sage! Medineto Renasainsu【Gurobaruwei Josho】

Renasa Science It announced that it was selected as a project under the Japan Agency for Medical Research and Development (AMED) “Industry-Academic Collaboration Innovation Promotion Project (Development and Commercialization)” for developing an artificial intelligence (AI) to predict the insulin dosage for diabetic patients. With AMED research grants, it will conduct clinical studies aimed at pharmaceutical approval for a diabetes treatment support system that uses AI as its core technology. The subsidy to be received in the fiscal year ending March 2023 is expected to be about 0.52 billion yen. The project period is three years, up to the fiscal year ending March 2025.